Oxygen saturation (medicine)

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, OSA, Interest, Growth, Food and Drug Administration, Insurance, Trial of the century, News, Investment, Oxygen saturation (medicine), Depreciation, Obstructive sleep apnea, FDA, Marketing, RPM, Food, Pharmaceutical industry

Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022.

Key Points: 
  • Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022.
  • I am proud of the 2023 results, and I look forward to building upon this momentum during 2024.”
    Financial Results for the Fourth Quarter and Year Ended December 31, 2023
    Revenues increased to $7.8 million for the fourth quarter ended December 31, 2023.
  • Fourth quarter 2023 sales and marketing expense reflects a modest increase compared to the quarter ended September 2023, and an increase of $1.0 million, or 40%, compared to the quarter ended December 2022.
  • Fourth quarter 2023 general and administrative expenses reflect an increase of $0.5 million, or 16%, compared to the quarter ended September 2023, and a decrease of $1.7 million, or 30%, compared to the quarter ended December 2022.

Movano Health Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, April 4, 2024
Blood pressure, COVID, Institutional review board, SOC, Obesity, Growth, Remote patient monitoring, Evie, D2C, Patient, Conditional sentence, Heart rate, Sleep, Workplace, Trial of the century, Woman, TAM, Oxygen saturation (medicine), Skin temperature, Hypoxia, FDA, Hand, RPM, Food, IRB, Pharmaceutical industry

PLEASANTON, Calif., April 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported fourth quarter and year end 2023 results and provided a business update.

Key Points: 
  • PLEASANTON, Calif., April 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported fourth quarter and year end 2023 results and provided a business update.
  • Movano Health achieved significant development milestones on its path to obtaining the FDA clearances necessary to launch the medical device version of the ring, Evie Med.
  • In October 2023, announced the results of its Institutional Review Board (IRB)-approved blood pressure clinical study.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update today at 2:00 pm PT/5:00 pm ET.

RAJANT HEALTH’S CUTTING-EDGE WEARABLE RECEIVES MEDICAL EXPERT ENDORSEMENTS

Retrieved on: 
Thursday, February 22, 2024
Sepsis, Artificial intelligence, AI, MD, Intelligence, Health, Oxygen saturation (medicine), Stroke, ECG, Learning, Life, Splenic infarction, Health care, Kinetic, Human back, Cowbell, Ecosystem, Patient, Medicine, FACC, Disease, Longevity, RHI, Medical device

Using medical devices that bridge patient information and patient data with healthcare providers is where information can affect the care of our patients.

Key Points: 
  • Using medical devices that bridge patient information and patient data with healthcare providers is where information can affect the care of our patients.
  • My interest in working with Rajant Health is driven by our growing need to access patient information and how it affects disease progression and medical management.
  • The scientists and engineers at Rajant Health are harnessing and incorporating artificial intelligence into multiple products, like Q-Stat, to care for patients more effectively.
  • After meeting with the team at Rajant Health and learning about the products they are developing, I was completely blown away.

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

Retrieved on: 
Thursday, February 22, 2024
P4, Bias, RPM, Doctor of Philosophy, OSA, MD, Sleep apnea, FDA, Obstructive sleep apnea, Bland–Altman plot, Oxygen saturation (medicine), Volunteering, Science, Gold, Disease, Oxygen saturation, Mortality, Pharmaceutical industry

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA).

Key Points: 
  • PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA).
  • “This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era.
  • The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory,” commented Len Liptak, Chief Executive Officer for ProSomnus Sleep Technologies.
  • “The results of the pilot testing hold tremendous promise for the formal validation testing, in which the ProSomnus RPMO2 OSA Device will be compared against a gold standard.”

Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, FDA, Medical Devices, Biometrics, Health, Bias, Hospital, Internet, Doctor of Philosophy, Medicine, Multimedia, MD, OTC, Asthma, Oxygen saturation (medicine), Pneumonia, Skin, Confusion, Communication, Pulse, Chronic obstructive pulmonary disease, Safety, Health care, COVID-19, Nursing, Patient, News, Lung cancer, Diagnosis, MASI, COPD, Medical device

Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.
  • View the full release here: https://www.businesswire.com/news/home/20240213849120/en/
    Joe Kiani, Founder and CEO of Masimo, said, “Until now, consumers and even healthcare providers had no way of knowing what pulse oximeter they could trust to use at home.
  • MightySat Medical provides a direct-to-consumer option for a medical device with hospital-grade pulse oximetry technology, Masimo SET®, whose performance has been reviewed and cleared by the FDA for medical use.
  • Now, MightySat Medical with Masimo SET® provides an FDA-cleared medical device with validated accuracy without the need for a prescription.

New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion

Retrieved on: 
Thursday, February 8, 2024
General Health, Health, Medical Devices, Hospitals, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Black and White, Carboxyhemoglobin, Perfusion, Bias, FDA, White, Skin, Pulse, Oxygen saturation, Multimedia, RD, Methemoglobin, Journal, Pigment, MASI, Oxygen saturation (medicine), DRS, Data, ARMS, Medical device

Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.

Key Points: 
  • Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.
  • To that end, they abstracted Pi values from their dataset, and divided them into “low perfusion” (Pi ≤ 1) and “normal perfusion” (Pi > 1) groups.
  • For the subset of Black subjects, there was bias and precision of -0.26% ± 1.37%, and for White subjects, -0.12% ± 1.31%.
  • In the low perfusion group, there was overall bias and precision of 0.48% ± 1.59%, with accuracy of 1.64% ARMS.

Sibel Announces its 4th FDA Clearance for Continuous Wearable Vital Signs Monitoring with ANNE® One and Additional Strategic Collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago

Retrieved on: 
Wednesday, February 7, 2024
Continuity, Research institute, Hospital, Research, Patient, Adolescence, Temperature, Lurie Children's Hospital, FDA, Vital signs, ECG, Entrepreneurship, Food, Health, Premature, Disability, Assistant, Neurology, Feinberg School of Medicine, Oxygen saturation (medicine), IZotope, Pleasure, Digital health, Nursing

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Sibel Health, a leading digital health company, announced today that its continuous wearable monitoring solution, ANNE® One, has received another 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements. In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.

Key Points: 
  • The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements.
  • In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.
  • Steve Xu MD, Co-Founder and CEO of Sibel Health, said "Our mission here at Sibel Health is to deliver Better Health Data for All®.
  • Sibel Health also announces a new collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago and its research enterprise, Stanley Manne Children's Research Institute.

Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress

Retrieved on: 
Monday, January 22, 2024
Hypoxia, Patient, Alcoholic hepatitis, Cirrhosis, ACLF, Respiratory failure, Society, Risk, Critical care, Mallinckrodt, Oxygen saturation (medicine), Congress, Boxed warning, Critical Care Medicine (journal), Clinical trial, Volume overload, HRS, SCCM, Use, SCR, Dietary supplement

DUBLIN, Jan. 22, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of findings from a post hoc analysis of the Phase 3 CONFIRM clinical trial. In this analysis, treatment with TERLIVAZ® (terlipressin) for injection was associated with improvements in verified hepatorenal syndrome (HRS) reversal and HRS reversal vs. placebo in adult cirrhosis patients with alcoholic hepatitis (AH) and HRS with rapid reduction in kidney function.1,2 The results will be shared in an oral presentation at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress, taking place January 21-23, 2024, in Phoenix, AZ.

Key Points: 
  • Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk.
  • Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO2 decreases below 90%.
  • Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed.
  • For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.

The Inspiration of Innovation, Kieslect Kr2 and Ks2 Smartwatches, Now Available in Malaysia for the First Time

Retrieved on: 
Wednesday, January 17, 2024
Woman, Heart rate, Sleep, GPU, Health, AMOLED, Life, Sunlight, Bluetooth, Prospectus, PPG, PD, FPS, Central processing unit, Oxygen saturation (medicine), KS-2, Shopee, Light-emitting diode, Muses, AOD, Fashion design

The brand officially debuts two fashionable and brilliant smartwatches, the Kieslect Kr2 and Ks2.

Key Points: 
  • The brand officially debuts two fashionable and brilliant smartwatches, the Kieslect Kr2 and Ks2.
  • The award-winning models received the Muse Design Award 2023, Kr2 and the New York Product Design Award 2023, Ks2.
  • Ms. Wei Lee, General Manager of Kieslect Malaysia, said, "Introducing Kr2 and Ks2 by Kieslect, where innovation meets elegance, we are thrilled to bring our cutting-edge technology and timeless design to Malaysia.
  • The ever-stylish Kieslect Kr2 and Ks2 are sure to add the right look and functions to your life.

Withings Announces BeamO The Revolutionary At-home Health Checkup

Retrieved on: 
Tuesday, January 9, 2024
LVCC, ECG, Hand, Heart rate, Overalls, Heart, Health, Electrode, Home, Thermoregulation, Atrial fibrillation, LED, History, Arrhythmia, PPG, Skin, Ventricular fibrillation, Movement, Fever, Oxygen saturation (medicine), Future, FDA, Physician, Wi-Fi, CES, Infection, Piezoelectricity, Smartphone, Medical device

With these capabilities, BeamO will conduct a 4-in-1 health checkup of body temperature, heart, and lung health in under a minute.

Key Points: 
  • With these capabilities, BeamO will conduct a 4-in-1 health checkup of body temperature, heart, and lung health in under a minute.
  • By automatically syncing with the Withings app through Wi-Fi, BeamO creates comprehensive health records over time.
  • To better track individual and family health journeys, Withings also introduces new capabilities within the Withings App for BeamO and its entire family of connected health products.
  • A CES Innovations Award Honoree, BeamO will be demoed during CES at the Withings Booth (LVCC NH #8637) .